- Open Access
COVID-19 and the RAAS—a potential role for angiotensin II?
Critical Care volume 24, Article number: 136 (2020)
- The Letter to this article has been published in Critical Care 2020 24:324
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated coronavirus disease 2019 (COVID-19) have wreaked havoc on healthcare systems globally. The potential for spread of this highly infectious virus, which is more transmissible and lethal than influenza, has reached pandemic proportions and has left many clinicians scrambling to provide care with scarce resources, all in the setting of no curative treatment, immunization, or effective therapy. Some candidate therapies include antivirals (remdesivir), antimalarials (hydroxychloroquine), and vaccines (mRNA-1273). Moreover, as we learn more about this virus, we have begun to draw some noteworthy conclusions regarding currently available ancillary “therapies” which may affect the natural history of the COVID-19 infection. Some of these “therapies” may actually be the avoidance of certain medications, like ibuprofen. Likewise, patients on angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) could be at a greater risk due to the mechanism by which SARS-CoV-2 enters the cell. It stands to reason that therapeutics that act counter to this mechanism may confer protection.
Angiotensin (Ang) II, the novel vasopressor agent recently approved in both the USA and Europe, may do just this. While its role as a vasopressor in shock is well known, its role in conferring protection from COVID-19, both to patients with shock and perhaps those without, is unknown and must be explored in this time of international crisis.
The level of critical illness attributable to COVID-19 has been recently described. In the recent outbreak in China, approximately 5% of patients with COVID-19 required ICU admission . In Italy, the prevalence of critical illness has surpassed rates seen in China, with ICU admission required for 12% of positive cases and 16% of all hospitalized patients . Critically ill patients are typically described as older with comorbidities, but cases involving young and healthy patients challenge this generalization [2, 3]. Patients are typically admitted to the ICU after 9–10 days of illness, commonly as a result of respiratory failure and acute respiratory distress syndrome (ARDS) . While less common than respiratory failure, septic shock may occur in a significant portion of patients with COVID-19, and is associated with increased mortality . A case series out of China described the incidence of shock in a cohort of hospitalized patients with COVID-19 to be 1.1%, but, in those with severe disease, incidence rose to 6.4% .
The renin-angiotensin-aldosterone system (RAAS) may be tied into the pathogenesis of the COVID-19 viral illness. The traditional RAAS pathway utilizes ACE1, primarily a pulmonary capillary endothelial enzyme, to convert AngI to AngII. As such, significant lung injury decreases the activity of pulmonary capillary endothelial-bound ACE. Initial reports from China demonstrate that approximately 40% of patients with severe illness have ARDS , increasing the risk for very low ACE1 function. Notably, inadequate ACE function is an independent predictor of mortality.
Specific to the SARS-CoV-2 virus, the SARS-coronavirus receptor utilizes ACE2 and the cellular protease TMPRSS2 to enter target cells (Fig. 1) . The spike protein on the viral surface of SARS-CoV-2 has been shown to bind to ACE2 with 10–20 times the affinity of SARS-CoV-1, the coronavirus responsible for the SARS outbreak in 2003 . The higher ACE2 affinity of SARS-CoV-2 may explain the ease of human-to-human transmission in the current pandemic . Preclinical studies of novel coronaviruses (e.g., SARS-CoV-1, SARS-CoV-2) highlight that the degree of ACE2 expression directly correlates to the degree of infectivity [9, 10]. Thus, strategies to decrease ACE2 expression may attenuate the impact of SARS-CoV-2 infection.
The endogenous mammalian peptide AngII is hypothesized to prevent infection from SARS-CoV-2 in multiple ways. First, because it normally binds to ACE2 during its degradation and hydrolysis into angiotensin-(1–7) , it may compete with the SARS-CoV-2 for the ACE2 receptor (Fig. 1). Second, the binding of AngII to the AT1 receptor has been shown to cause internalization and downregulation of ACE2 through an ERK1/2 and p38 MAP kinase pathway in both in vitro animal and in vivo human models [12, 13]. Third, AngII has been shown to cause AT1 receptor-dependent destruction of ACE2 through ubiquitination and transport into lysosomes. The competitive inhibition, downregulation, internalization, and then degradation of ACE2 may decrease the degree of viral infection by interfering with host cell entry of the virus. Much has been made of the hypothetical risk of COVID-19 in the setting ACE inhibitors and ARBs, which have been shown by multiple investigators to increase expression or activity of ACE2 [14, 15]. In fact, severe COVID-19 disease has been described in patients with conditions known to be associated with RAAS blockade therapy, such as hypertension and diabetes mellitus . However, to date, the link between ACE inhibitors and ARBs and severity of illness of SARS-CoV-2 infection is purely speculative. Both the American College of Cardiology and the European Society of Cardiology have published statements advising against the discontinuation of ACE inhibitors and ARBs in SARS-CoV-2.
The support of MAP with AngII in the setting of SARS-CoV-2 infection seems physiologically rational, given the aforementioned hypotheses (Table 1). Due to the large number of critically ill SARS-CoV-2 patients, AngII has been made available in Italy, Germany and the United Kingdom for compassionate use because, despite approval by the European Medicines Agency, it is not yet commercially available in Europe. Perhaps we will learn some important lessons from these patients, so as to inform our efforts going forward. For instance, should AngII be used for all COVID-19 patients in shock? Should it be considered earlier in the course of disease, perhaps as a first-line vasopressor? Finally, and more controversially, should we evaluate the modulating effects of AngII on ACE2 for the treatment of COVID-19 in patients without shock? AngII use has been described at sub-pressor doses, and multiple studies have shown that higher levels of MAP may not be harmful. As the SARS-CoV-2 pandemic evolves, we must consider any form of therapy that may “flatten” the curve (https://www.flattenthecurve.com). The physiologic relationship between ACE2 and angiotensin II is persuasive, and given the enormity of the situation, we are obligated to explore this therapy as a potential avenue of treatment.
Availability of data and materials
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. [Epub ahead of print].
Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020. [Epub ahead of print].
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. [Epub ahead of print].
Murthy S, Gomersall CD, Fowler RA. Care for critically ill patients with COVID-19. JAMA. 2020. [Epub ahead of print].
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. [Epub ahead of print].
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al. SARS-CoV-2 CellEntry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. [Epub ahead of print].
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–3.
Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.
Hofmann H, Geier M, Marzi A, Krumbiegel M, Peipp M, Fey GH, Gramberg T, Pohlmann S. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun. 2004;319(4):1216–21.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450–4.
Chawla LS, Chen S, Bellomo R, Tidmarsh GF. Angiotensin converting enzyme defects in shock: implications for future therapy. Crit Care. 2018;22(1):274.
Koka V, Huang XR, Chung AC, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol. 2008;172(5):1174–83.
Fernandes T, Hashimoto NY, Magalhaes FC, Fernandes FB, Casarini DE, Carmona AK, Krieger JE, Phillips MI, Oliveira EM. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-angiotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1-7). Hypertension. 2011;58(2):182–9.
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–10.
Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–6.
The authors received no funding related to this manuscript.
Ethics approval and consent to participate
Consent for publication
JHC serves on the Speaker’s Bureau for La Jolla Pharmaceutical Company.
All other authors report no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Busse, L.W., Chow, J.H., McCurdy, M.T. et al. COVID-19 and the RAAS—a potential role for angiotensin II?. Crit Care 24, 136 (2020). https://doi.org/10.1186/s13054-020-02862-1
- Angiotensin II